Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.
about
In Vivo Tracking of Human Hematopoiesis Reveals Patterns of Clonal Dynamics during Early and Steady-State Reconstitution PhasesOptimizing Stem Cells Mobilization Strategies to Ameliorate Patient Outcomes: A Review of Guide- lines and Recommendations.Impact of lenalidomide-based induction therapy on the mobilization of CD34(+) cells, blood graft cellular composition, and post-transplant recovery in myeloma patients: a prospective multicenter study.Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.Hematopoietic progenitor cell mobilization for autologous transplantation - a literature review.A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.Performance assessment and benchmarking of autologous peripheral blood stem cell collection with two different apheresis devices.Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.Mobilization of hematopoietic progenitor cells for autologous transportation: consensus recommendations.Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group.Notch2 blockade enhances hematopoietic stem cell mobilization and homing.Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.Addition of plerixafor to G-CSF is useful to achieve efficient collection even in very poor mobilizers: hope for patients with diminished hematopoietic function.Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group.Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.Dynamic cellular phynotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1α versus synthetic agents.UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score.Plerixafor: what we still have to learn.Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the "on-demand" scheme of administration at French autologous hematopoietic stem cell transplant programs.Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.
P2860
Q37089345-4DBFDF6E-99C4-4EC4-9C39-362E5F57A849Q37682128-2B192957-096D-4099-8030-5DE2943B7965Q38691698-188023E1-5393-4772-B4EF-721899219B01Q38707629-9EF5E6DF-39EF-4AD9-A9DC-0683322A2851Q38771080-AF83237A-5E9D-467D-A491-E8D0695CB22EQ38771752-1393BCA0-B9DB-4DC0-8C65-B073FE865C65Q38859426-22632062-FBCB-45BB-B8B7-D93EF17C79F7Q38880504-81668D3F-15D6-4D9B-AC0B-394E0699247BQ39303533-2E75FC1B-59E6-4F4B-8283-1A0EC390ABD9Q40081439-00F1A867-5BA9-421F-BBB0-1F2DB446A4BFQ40407349-88145E77-5B11-41E4-AE0B-31BF64FFF3C7Q40490106-0342DC11-BCBF-430C-9F5A-A4A2719046BBQ41092832-30C0DBA8-1382-44F1-BD7A-840948D82B5EQ42368326-6DFC4F1F-4705-4977-AE8A-8A5D2148E15FQ44256421-3FD2B4DC-4AE2-4A0A-982F-B281E4135658Q47575272-619E0C2E-7606-490E-8978-1E122CEAA4D0Q47914097-8ACDA218-1342-4F7D-9A03-68E557313085Q47967442-86CDD490-E033-4190-B409-4657CEA72BD6Q48097743-6FB84F0A-D440-44F0-B423-2B05B9B79AC0Q48138880-454A493F-3D95-4D7D-8C24-37C629AAA7CEQ48251584-FA89EA43-4CBA-4EFF-B92B-D2B35610EBE6Q48251589-BD1B6F53-3C45-405E-9BA4-27F2D89557BBQ48747463-7BBF85C1-FC4E-4DD3-9540-89D8467FE580Q51057684-B1A6FE2F-AE2A-4253-A01D-DF700B60C7CBQ53130499-2CD2C62C-8AF4-4BB3-9EBB-2480BE74E151Q53508311-F43496BB-060C-4C22-9807-B2C1AD83F785Q55094338-CBCB4333-9F67-4122-B806-3284DCEAE941
P2860
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Autologous haematopoietic stem ...... od and Marrow Transplantation.
@en
type
label
Autologous haematopoietic stem ...... od and Marrow Transplantation.
@en
prefLabel
Autologous haematopoietic stem ...... od and Marrow Transplantation.
@en
P2093
P2860
P50
P356
P1476
Autologous haematopoietic stem ...... ood and Marrow Transplantation
@en
P2093
C Chabannon
D Selleslag
H C Schouten
J Apperley
P2860
P2888
P304
P356
10.1038/BMT.2014.39
P407
P577
2014-03-31T00:00:00Z
P5875
P6179
1013743850